Abstract
Sclerostin, a glycoprotein involved in vascular calcification, could play a role in cardiovascular disorders. Obstructive sleep apnea (OSA) is frequently associated with cardiovascular comorbidities. Thus, in this study we set out to assess the level of sclerostin in patients with OSA. Sclerostin was evaluated in the serum by ELISA method in 106 patients (43 women) with OSA of the mean age of 55 ± 10 years, BMI of 33.1 ± 7.9 kg/m2, and apnea/hypopnea index (AHI) of 29.7 ± 18.9. There were 76 (72 %) patients with cardiovascular comorbidities in the OSA group. The results were compared with those in 49 healthy control subjects. We found that the level of sclerostin was higher in the female OSA patients than that in female controls (80.1 ± 36.5 pg/ml vs. 61.4 ± 24.1 pg/ml; p < 0.05) and it correlated with AHI (rs = 0.32, p < 0.01) and desaturation index (rs = 0.34, p < 0.01). Further, in OSA women with cardiovascular comorbidities, sclerostin was higher than in women without such comorbidities (87.0 ± 37.4 pg/ml vs. 57.3 ± 22.1 pg/ml; p < 0.05). In men, there were no differences in the serum sclerostin level between the OSA and control subjects, nor was there any relationship with cardiovascular diseases. In conclusion, increased serum sclerostin coincides with the severity of OSA and its cardiovascular sequelae in female patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH (2011) Determinants of serum sclerostin in health pre- and postmenopausal women. J Bone Miner Res 26(12):2812–2822
Balci M, Kirkpantur A, Turkvatan A, Mandiroglu S, Ozturk E, Afsar B (2013) Sclerostin as a new key player in arteriovenous fistula calcification. Herz 40(2):289–297
Catalano A, Pintaudi B, Morabito N, Di Vieste G, Giunta L, Bruno ML, Cucinotta D, Lasco A, Di Benedetto A (2014) Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus. Eur J Endocrinol 171(3):293–300
Claes KJ, Viaene L, Heve S, Meijers B, d’Haese P, Evenepoel P (2013) Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 98(8):3221–3228
Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G (2013) Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol 62(7):569–576
Drechsler C, Evenepoel P, Vervloet MG, Wanner C, Ketteler M, Marx N, Floege J, Dekker FW, Brandenburg VM (2014) High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 30(2):288–293
Eyrard S, Delanave P, Kamel S, Cristol JP, Cavalier E, SFBC/SN joined working group on vascular calcifications (2014) Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta 438:401–414
Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, Morales-Santana S, Garcia-Fontana B, Garcia-Salcedo JA, Munoz-Torres M (2012) Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 97(1):234–241
Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML (2013) The relationship between inhibitors of the Wnt signaling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone 56(1):42–47
Kendzerska T, Gershon AS, Hawker G, Leung RS, Tomlinson G (2014) Obstructive sleep apnea and risk of cardiovascular events and all-cause mortality: a decade –long historical cohort study. PLoS Med 11(2):e1001599
Klangjareonchai T, Nimitphong H, Saetung S, Bhirommuang N, Samittarucksa R, Chanprasertyothin S, Sudatip R, Ongphiphadhanakul B (2014) Circulating sclerostin and irisin are related and interact with gender to influence adiposity in adults with prediabetes. Int J Endocrinol 2014:261545. doi:10.1155/2014/261545
Lavie L, Lavie P (2009) Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J 33:1467–1484
Li QY, Feng Y, Lin YN, Li M, Guo Q, Gu SY, Liu JL, Zhang RF, Wan HY (2014) Gender difference in protein expression of vascular wall in mice exposed to chronic intermittent hypoxia: a preliminary study. Genet Mol Res 13(4):8489–8501
Mac Donald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17(1):9–26
Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95(4):1991–1997
Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87(2):99–107
Morales-Santana S, Garcia-Fontana B, Garcia-Martin A, Rozas-Moreno P, Garcia-Salcedo JA, Reyes-Garcia R, Munoz-Torres M (2013) Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 36(6):1667–1674
Sheng Z, Tong D, Ou Y, Zhang H, Zhang Z, Li S, Zhou J, Zhang J, Liao E (2012) Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. Clin Endocrinol (Oxf) 76(6):797–801
Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA (2004) Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35(4):828–835
Urano T, Shiraki M, Ouchi Y, Inoue S (2012) Association of circulating sclerostin levels with fat mass and metabolic disease—related markers in Japanese postmenopausal women. J Clin Endocrinol Metab 97(8):E1473–E1477
Wells JC (2007) Sexual dimorphism of body composition. Best Pract Res Clin Endocrinol Metab 21(3):415–430
Won C, Guilleminault C (2015) Gender differences in sleep disordered breathing: implications for therapy. Expert Rev Respir Med 9(2):221–231
Zhu D, Mackenzie NC, Millan JL, Farguharson C, MacRae VE (2011) The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 6(5):e19595
Competing Interests
The authors declare that they have no competing interests in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Kosacka, M., Porębska, I., Brzecka, A. (2015). Sclerostin in Obstructive Sleep Apnea. In: Pokorski, M. (eds) Respiratory Medicine and Science. Advances in Experimental Medicine and Biology(), vol 910. Springer, Cham. https://doi.org/10.1007/5584_2015_202
Download citation
DOI: https://doi.org/10.1007/5584_2015_202
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-30658-2
Online ISBN: 978-3-319-30659-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)